TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33957371
Drug: Rasburicase (1.5−3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasburicase (1.5−3 mg) with allopurinol 300 mg daily
Study: 34260549
Drug: Group Rational
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Rational Emotive Behavior Therapy (group REBT)
Study: 32213019
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for acute and chronic pouchitis
Study: 33612439
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplementation (16 g/d)
Study: 33612439
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein supplementation (16 g/d)
Study: 33612439
Drug: Whey-soy blended
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey-soy blended protein supplementation (16 g/d)
Study: 36277594
Drug: Sequential ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential ventilation therapy
Study: 33902955
Drug: Chemotherapy (vinflunine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (vinflunine 320 mg/m2, paclitaxel 175 mg/m2, or docetaxel 75 mg/m2 according to investigator choice) every 3 weeks
Study: 34195784
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia alone with postoperative intravenous analgesia
Study: 35780458
Drug: Health care
Normalized name: Health Care Lancing Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health care worker training intervention (SISTAQUIT) including ABCD approach, educational resource package, free oral nicotine replacement therapy, implementation support, and trial implementation training
Study: 32703215
Drug: Health worker
Normalized name: Apis cerana worker secretion preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health worker knowledge of artesunate treatment policies
Study: 32703215
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of dosing intervals
Study: 32703215
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of preparation solutions
Study: 32703215
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of artesunate dose for weight categories
Study: 32703215
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of preferred route of administration
Study: 32703215
Drug: Display of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Display of artesunate administration posters
Study: 33063157
Drug: Hypo group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypo group (glucose < 3.3 mmol/L)
Study: 33063157
Drug: Non-hypo group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-hypo group (glucose ≥ 3.3 mmol/L)
Study: 35108175
Drug: Temporary transvenous
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary transvenous diaphragm neurostimulation (treatment)
Study: 34266934
Drug: ProDisc-L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProDisc-L
Study: 35348880
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention (20 min oral presentation based on literature and international guidelines)
Study: 32818953
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both (sensory substitution device and white cane)
Study: 33905530
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) plus radiation therapy (RT)
Study: 34275765
Drug: Tart Cherry
Normalized name: Tart Cherry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tart Cherry (TC) concentrate (50 tart cherries), 1 Oz in 8 Oz water daily for 6 weeks
Study: 34275765
Drug: Placebo (syrup)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (syrup)
Study: 33639391
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches (received at baseline)
Study: 32998924
Drug: Topical chlorhexidine
Normalized name: chlorhexidine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical chlorhexidine 0.2%
Study: 36348276
Drug: Pyridostigmine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (60 mg/day)
Study: 36400384
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (nCT) followed by minimally invasive esophagectomy (MIE)
Study: 35152152
Drug: Intravenous nafamostat
Normalized name: Nafamostat
DrugBank: Nafamostat (DB12598)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Intravenous nafamostat (0.2 mg/kg/h for a maximum of seven days)
Study: 36514143
Drug: Intravenous nafamostat
Normalized name: Nafamostat
DrugBank: Nafamostat (DB12598)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Intravenous nafamostat
Study: 32187789
Drug: Biomedical-focused education
Normalized name: hypromellose
DrugBank: Hypromellose (DB11075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomedical-focused education and exercise therapy
Study: 32321551
Drug: Statin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin plus fenofibrate (rosuvastatin 10 mg plus fenofibrate 160 mg/day)
Study: 32321551
Drug: Statin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin alone (rosuvastatin 10 mg/day)
Study: 32725954
Drug: Ibuprofen syrup
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen syrup 10 mg/kg
Study: 33275668
Drug: Novel targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel targeted agents (ibrutinib, acalabrutinib, venetoclax)
Study: 33275668
Drug: Chemotherapy-free frontline
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-free frontline treatment approaches
Study: 36108617
Drug: Antiparasitic antibiotic
Normalized name: ANTIPARASITICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiparasitic antibiotic treatment in Group A
Study: 35902351
Drug: Olezarsen (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olezarsen (50 mg every 4 weeks)
Study: 33296258
Drug: Acupressure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure treatment (performed two times a week for 4 weeks)
Study: 35115351
Drug: Motor control
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor control and manual therapy
Study: 35055807
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planning (SRP) plus gaseous ozone therapy (GROUP A)
Study: 35055807
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (GROUP B)
Study: 35706482
Drug: NEVERMIND e-health
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEVERMIND e-health system (smart shirt and mobile application with lifestyle behavioural advice, mindfulness-based therapy, and cognitive behavioural therapy)
Study: 35489648
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (1mg/kg body weight Enoxaparin, subcutaneously, 12 hourly for seven days)
Study: 35489648
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for pancreatitis (Control group)
Study: 33684508
Drug: Behavioral, lifestyle,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral, lifestyle, and psychological therapy interventions
Study: 36130048
Drug: PEG‐rhGH 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐rhGH 0.1 mg/kg/week (low-dose group)
Study: 36130048
Drug: PEG‐rhGH 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐rhGH 0.2 mg/kg/week (high-dose group)
Study: 34496277
Drug: Written Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written Exposure Therapy enhanced with Crisis Response Planning for suicide risk
Study: 37980801
Drug: Written Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written Exposure Therapy
Study: 35017325
Drug: N-acetylcysteine (NAC;
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC; 1200 mg)
Study: 35017325
Drug: Omega 3
Normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omega 3 fatty acids (4 g)
Study: 34000049
Drug: Fezolinetant 180
Normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fezolinetant 180 mg/day
Study: 34000049
Drug: Fezolinetant 60
Normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fezolinetant 60 mg/day
Study: 32860331
Drug: Overall sample
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall sample adherence to oral therapy
Study: 32860331
Drug: Treatment-emergent symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent symptoms
Study: 35684157
Drug: SAGAT (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGAT (combination of serine, alanine, glutamate, aspartate, and tyrosine)
Study: 33249630
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg HS-10234
Study: 33249630
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg HS-10234
Study: 33249630
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg HS-10234
Study: 33249630
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Tenofovir disoproxil fumarate (TDF)
Study: 36009012
Drug: Low-energy/fat diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy/fat diet (1200–1500 Kcal/day and 15–20% lipids) + Monacolin K (5 mg) + Astaxanthin (0.1 mg)
Study: 39133200
Drug: secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab 150 mg
Study: 36007918
Drug: Nicotine exposure
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine exposure (maternal urine cotinine >5 ng/mL)
Study: 36007918
Drug: Heavy nicotine
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy nicotine exposure (>100 ng/mL)
Study: 36007918
Drug: Mild nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild nicotine exposure (5-100 ng/mL)
Study: 32174360
Drug: Visual-to-auditory sensory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual-to-auditory sensory substitution devices (SSDs) using The vOICe; specific dosage and duration not mentioned.
Study: 32174360
Drug: Standard dichotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dichotic listening test; specific dosage and duration not mentioned.
Study: 35771346
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation (400 kcal and 15 g protein daily, multivitamin tablets thrice weekly for 3 months)
Study: 35771346
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 kcal and 2 g protein daily, placebo tablet thrice weekly for 3 months)
Study: 32005582
Drug: Self-administered artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Self-administered artesunate vaginal inserts (1, 2, or 3 five-day treatment cycles at study weeks 0, 2, and 4)
Study: 32005582
Drug: Self-administered artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Self-administered artesunate vaginal inserts
Study: 34479543
Drug: Canagliflozin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin (100 mg daily)
Study: 34479543
Drug: Glimepiride (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (starting dose 0.5 mg daily)
Study: 32258159
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of muscle energy technique (MET) and ischemic compression technique (ICT) along with conventional intervention
Study: 38279390
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 52-week prednisone taper
Study: 33011684
Drug: Compression sutures
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compression sutures combined with intracameral air injection (CSAI)
Study: 32513581
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg soy isoflavone daily for 8 weeks
Study: 36476258
Drug: Typhoid Vi-polysaccharide
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid Vi-polysaccharide conjugate vaccine (Typbar-TCV®) and measles vaccine (MV) concomitantly at 9 months (Group 1)
Study: 36476258
Drug: Typhoid Vi-polysaccharide
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid Vi-polysaccharide conjugate vaccine (Typbar-TCV®) and measles vaccine (MV) on Day 0 and Day 28 (Group 2)
Study: 36476258
Drug: Typhoid Vi-polysaccharide
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid Vi-polysaccharide conjugate vaccine (Typbar-TCV®) at 8 months and MV 28 days later (Group 3)
Study: 36476258
Drug: Measles vaccine
Normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles vaccine only at 9 months (Group 4)
Study: 32559353
Drug: PSMA radioligand
Normalized name: Gallium-68 PSMA
DrugBank: Gallium-68 PSMA (DB16303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSMA radioligand therapy (RLT) with 177Lu (Lu-PSMA)
Study: 32830894
Drug: Canakinumab 300
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab 300 mg IV
Study: 32830894
Drug: Canakinumab 600
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab 600 mg IV
Study: 34625562
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (AC) after ALND
Study: 34625562
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (AC) before ALND
Study: 36423444
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic bowel preparation (OABP)
Study: 36423444
Drug: OABP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: OABP plus mechanical bowel preparation (MBP)
Study: 34338231
Drug: Doxycycline added
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline added to standard antituberculous therapy (ATT) for 2 weeks
Study: 34338231
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to standard antituberculous therapy (ATT)
Study: 32827483
Drug: Oral metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metronomic chemotherapy (15 mg/m2 methotrexate once per week plus 200 mg celecoxib twice per day until disease progression or intolerable side effects)
Study: 32827483
Drug: Intravenous cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisplatin (75 mg/m2 once every 3 weeks for six cycles)
Study: 32827483
Drug: Oral metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metronomic chemotherapy
Study: 33684325
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (20, 75-min, in-person, group, gentle yoga classes held twice weekly)
Study: 34151602
Drug: Interactive virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive virtual reality treatment over ten sessions
Study: 34151602
Drug: Interactive virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive virtual reality treatment
Study: 32162103
Drug: THC (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (low dose)
Study: 35477628
Drug: Dexmedetomidine ODF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine ODF 180 mcg
Study: 35477628
Drug: Dexmedetomidine ODF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine ODF 120 mcg
Study: 35477628
Drug: Dexmedetomidine ODF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine ODF (both doses)
Study: 32937627
Drug: Intravesical administration
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical administration of melatonin (25 mg)
Study: 32937627
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of melatonin (25 mg)
Study: 32937627
Drug: Transdermal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal administration of melatonin (25 mg)
Study: 32937627
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of melatonin (25 mg)
Study: 32937627
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of melatonin (25 mg)
Study: 34288578
Drug: Avanafil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avanafil (200 mg) under fasting conditions
Study: 34288578
Drug: Avanafil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avanafil (200 mg) under fed conditions
Study: 34288578
Drug: Avanafil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avanafil (200 mg)
Study: 33597336
Drug: Systemic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic administration of vitamin C (600 mg)
Study: 33597336
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of local and systemic administration of vitamin C (600 mg)
Study: 33597336
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vitamin C administration)
Study: 33207670
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment group (Control Group)
Study: 32595244
Drug: WS 1442
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS 1442 2x450 mg/day (WS-standard)
Study: 32595244
Drug: WS 1442
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS 1442 2x900 mg/day (WS-double)
Study: 32119742
Drug: Preventive Zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive Zinc Supplementation (PZ; 7 mg Zn/d)
Study: 32490642
Drug: Intensive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antihypertensive treatment with aspirin
Study: 33784735
Drug: Aflibercept injections
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept injections (2.0 mg)
Study: 32242987
Drug: P. palmata
Approvals — FDA: no, EMA: no, PMDA: no
Description: P. palmata (2 g/day)
Study: 33909135
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy (chemoradiotherapy)
Study: 35857290
Drug: Topical synthetic
Normalized name: conjugated estrogens topical synthetic A, 0.625 mg/g vaginal cream with applicator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical synthetic hypericin ointment, 0.25%, activated with visible light, applied to 3 index lesions twice weekly for 6 weeks (Cycle 1)
Study: 35857290
Drug: Topical synthetic
Normalized name: conjugated estrogens topical synthetic A, 0.625 mg/g vaginal cream with applicator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical synthetic hypericin ointment, 0.25%, activated with visible light, applied to index lesions for 6 weeks (Cycle 2)
Study: 35857290
Drug: Topical synthetic
Normalized name: conjugated estrogens topical synthetic A, 0.625 mg/g vaginal cream with applicator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical synthetic hypericin ointment, 0.25%, activated with visible light, applied to index and additional lesions for 6 weeks (Cycle 3)
Study: 35857290
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied to 3 index lesions twice weekly for 6 weeks (Cycle 1)
Study: 35857290
Drug: Topical synthetic
Normalized name: conjugated estrogens topical synthetic A, 0.625 mg/g vaginal cream with applicator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical synthetic hypericin ointment, 0.25%, activated with visible light (all cycles)
Study: 32544602
Drug: Concordant clinician
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concordant clinician (CC)
Study: 34053249
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) plus traditional physical therapy program (TPTP)
Study: 34053249
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical therapy program (TPTP)
Study: 33651414
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment for Bell's palsy
Study: 32277800
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure treatment protocol for children and adolescents (PE‐A)
Study: 32537711
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of oral antibiotics (standard arm)
Study: 32537711
Drug: Stoppage of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stoppage of antibiotics (experimental arm)